Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547131 · ClinicalTrials.gov registry record · Phase 1
Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00547131 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT00547131, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Collecting fluid samples through a catheter may help doctors find out how well temozolomide spreads throughout the brain. PURPOSE: This clinical trial is studying temozolomide in treating patients with primary brain tumors or metastatic brain tumors.
Interventions
- OTHER laboratory biomarker analysis
- DRUG temozolomide
- OTHER pharmacological study
- OTHER mass spectrometry
- OTHER liquid chromatography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547131
The ClinicalTrials.gov registry entry for NCT00547131 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00547131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547131 about?
NCT00547131 is a clinical study titled "Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors". RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Collecting fluid samples through a catheter may help doctors find out how well temozolomide spreads throughout the bra...
What is the current status of trial NCT00547131?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00547131?
The interventions under investigation include: laboratory biomarker analysis (OTHER), temozolomide (DRUG), pharmacological study (OTHER), mass spectrometry (OTHER), liquid chromatography (OTHER).
Who is sponsoring clinical trial NCT00547131?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.